BCR and B-cell chronic lymphocytic leukemia: Given the PKD implication in BCR-dependent CXCR4/CXCR5 internalization and CLL cell migration, targeting PKD could be an interesting alternative therapeutic option that would circumvent the PI3K-δ inhibitors side effects that target ΑΚΤ/mTor signaling pathways [64].